As expected, a significant decline in the number of CD11c+ DCs (Additional file 1: Figure S2d), particularly CD103+CD11c+ and CD8α+CD11c+ DCs, was observed in tumor-infiltrating lymphocytes of DEXP&A2&N-treated Batf3−/− compared to wild-type mice (Fig. 2h, i). This evidence concerns the gene BATF3 and neoplasm.